Sign in

Private company

Affimed N.V.

In its 2024 annual report (Form 20-F) the company says: “We are a clinical-stage immuno-oncology company focused on developing highly targeted cancer immunotherapies. Our product candidates represent an innovative approach to cancer treatment that seeks to harness the body’s own immune defenses to fight tumor cells. Our innate cell engagers have the ability to bring innate immune cells into the proximity of tumor cells and trigger an activation cascade that leads to the destruction of cancer cells.”4

Last updated Oct 21, 2026.

Overview

8.3MRevenue, fiscal 20232
-105.9MNet income, fiscal 20232
  • IndustryPharmaceutical Preparations1
  • Headquarters2M1
  • Incorporated inGermany3
  • Business addressGottlieb-Daimler-Strasse 2, Mannheim, 2M 681653
  • Filer categoryAccelerated filer3

See how the biggest companies compare on our leaderboards

We are a clinical-stage immuno-oncology company focused on developing highly targeted cancer immunotherapies. Our product candidates represent an innovative approach to cancer treatment that seeks to harness the body’s own immune defenses to fight tumor cells. The most potent cells of the human defense arsenal are types of white blood cells called innate immune cells (NK cells and macrophages) and T cells. Leveraging our fit-for-purpose ROCK ® platform, we develop proprietary, next-generation bispecific antibodies, so-called innate cell engagers (ICE ® ), which are designed to direct innate immune cells and establish a bridge to cancer cells. Our innate cell engagers have the ability to bring innate immune cells into the proximity of tumor cells and trigger an activation cascade that leads to the destruction of cancer cells. Due to their novel tetravalent architecture with four binding d…4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from. Figures are in EUR, the currency the company reports in.

Key numbers, fiscal 2023

-1289.0%Operating margin2
-1280.2%Net margin2
-80.0%Revenue growth, 20232
-183.3%Return on equity2
0.11×Debt to equity2
-114.0M EURFree cash flow2

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Research and development100¢95.0M EUR
  • Income tax0¢3.0K EUR

Out of 8.3M EUR in revenue.2 The company lost money this year.

Financial statements

Revenue5678928.3M EUR in 2023+31% since 2016
020.0M EUR40.0M EUR60.0M EUR2016: 6.3M EUR6.3M EUR20162017: 2.0M EUR2.0M EUR2017−68%2018: 23.7M EUR23.7M EUR2018+1081%2019: 21.4M EUR21.4M EUR2019−10%2020: 28.4M EUR28.4M EUR2020+33%2021: 40.4M EUR40.4M EUR2021+42%2022: 41.4M EUR41.4M EUR2022+2%2023: 8.3M EUR8.3M EUR2023−80%
Operating income567892-106.7M EUR in 2023+233% since 2016
-150.0M EUR-100.0M EUR-50.0M EUR02016: -32.0M EUR-32.0M EUR20162017: -27.3M EUR-27.3M EUR2017−15%2018: -19.5M EUR-19.5M EUR2018−28%2019: -32.4M EUR-32.4M EUR2019+66%2020: -34.7M EUR-34.7M EUR2020+7%2021: -64.0M EUR-64.0M EUR2021+84%2022: -88.1M EUR-88.1M EUR2022+38%2023: -106.7M EUR-106.7M EUR2023+21%
Net income567892-105.9M EUR in 2023+229% since 2016
-150.0M EUR-100.0M EUR-50.0M EUR02016: -32.2M EUR-32.2M EUR20162017: -30.2M EUR-30.2M EUR2017−6%2018: -19.5M EUR-19.5M EUR2018−36%2019: -32.4M EUR-32.4M EUR2019+66%2020: -41.4M EUR-41.4M EUR2020+28%2021: -57.5M EUR-57.5M EUR2021+39%2022: -86.0M EUR-86.0M EUR2022+50%2023: -105.9M EUR-105.9M EUR2023+23%
Fiscal year20162017201820192020202120222023
Revenue6.3M EUR52.0M EUR623.7M EUR721.4M EUR828.4M EUR940.4M EUR241.4M EUR28.3M EUR2
Research and development81.5M EUR298.8M EUR295.0M EUR2
Operating income-32.0M EUR5-27.3M EUR6-19.5M EUR7-32.4M EUR8-34.7M EUR9-64.0M EUR2-88.1M EUR2-106.7M EUR2
Income before tax-57.5M EUR2-86.0M EUR2-105.9M EUR2
Income tax2.0K EUR22.0K EUR23.0K EUR2
Net income-32.2M EUR5-30.2M EUR6-19.5M EUR7-32.4M EUR8-41.4M EUR9-57.5M EUR2-86.0M EUR2-105.9M EUR2
Earnings per share-0 EUR/shares9-5 EUR/shares2-6 EUR/shares2-7 EUR/shares2
Earnings per share (diluted)-0 EUR/shares9-5 EUR/shares2-6 EUR/shares2-7 EUR/shares2
Shares (weighted, basic)119.5M shares8

Compare Affimed N.V. with another company

Corporate structure

Affimed N.V. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Affimed N.V.

  • Affimed N.V. 2M

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Affimed N.V. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net4.9M EUR2 Dec 31, 20233.8M EUR2 Dec 31, 2022+28.3%
Operating-lease assets (leased space)8.0M EUR2 Dec 31, 2023561.0K EUR2 Dec 31, 2022+1333.0%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents38.5M EUR2 Dec 31, 2023190.3M EUR2 Dec 31, 2022−79.8%
Long-term investments0 EUR9 Dec 31, 202212.3M EUR9 Dec 31, 2021−100.0%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)25.0K EUR2 Dec 31, 202358.0K EUR2 Dec 31, 2022−56.9%

Inventory

ItemLatestA year beforeChange
Inventory, total463.0K EUR2 Dec 31, 2023628.0K EUR2 Dec 31, 2022−26.3%

Former names

  • Affimed Therapeutics B.V.May 23, 2014 to Sep 16, 20143

Filings

80 filings to the SEC since October 2021: 3 annual reports, 17 large holders, 60 other. The latest 20:

  1. May 20, 2025SCHEDULE 13G/A EDGAR
  2. May 14, 20256-K EDGAR
  3. May 13, 20256-K EDGAR
  4. May 1, 2025NT 20-F EDGAR
  5. Apr 21, 20256-K EDGAR
  6. Feb 14, 2025SCHEDULE 13G/A EDGAR
  7. Dec 17, 20246-K EDGAR
  8. Nov 14, 20246-K EDGAR
  9. Nov 8, 2024EFFECT EDGAR
  10. Nov 8, 2024424B5 EDGAR
  11. Nov 8, 2024CORRESP EDGAR
  12. Nov 7, 2024UPLOAD EDGAR
  13. Nov 4, 2024F-3 EDGAR
  14. Oct 24, 2024SC 13G 683 CAPITAL MANAGEMENT, LLC EDGAR
  15. Oct 15, 20246-K EDGAR
  16. Sep 11, 20246-K EDGAR
  17. Sep 5, 20246-K EDGAR
  18. Sep 3, 20246-K EDGAR
  19. Jun 26, 20246-K EDGAR
  20. Jun 12, 20246-K EDGAR

The 80 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Affimed N.V. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAffimed N.V.1
  • CIK0001608390
  • Filer statusAccelerated filer1
  • Incorporated inGermany1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business addressGottlieb-Daimler-Strasse 2, Mannheim, 2M 681651
  • Phone49-621-5600301
  • Shares outstanding15,227,463 as of Dec 31, 20232
  • On EDGAR sinceMay 23, 20141
  • Filings310 in all: 6-K (127), SC 13G/A (31), SC 13D/A (28), SC 13G (24), 424B5 (16), CORRESP (11), 20-F (10), SC 13D (10)1
    All 31 form types

    UPLOAD (8), EFFECT (7), F-1/A (7), F-3 (4), 6-K/A (3), 424B4 (2), CT ORDER (2), F-1 (2), POS EX (2), S-8 (2), SCHEDULE 13G/A (2), 20-F/A (1), 25-NSE (1), 8-A12B (1), CERTNAS (1), DRS (1), F-1MEF (1), F-3/A (1), F-3ASR (1), FWP (1), NT 20-F (1), POS AM (1), POSASR (1)

  • Latest filingsAnnual report (20-F) Mar 28, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15